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Available online xxxxObjective: To measure breast tissue and serum LNG concentrations in women using a LNG-IUS.
Study design: This pilot study was performed in 25 healthy women undergoing breast surgery at the Ghent Uni-
versity hospital. LNG concentrations were measured in serum and microdissected breast tissue samples using a
validated ultra-performance liquid chromatography/tandem mass spectrometry assay.
Result(s): The mean LNG concentration in the 18 LNG-IUS users was 0.18±0.16 ng/mL in serum and 0.26±0.28
ng/g in breast tissue. For four women without any form of hormonal contraceptive (the negative controls), the
mean concentrations were below the limit of quantiﬁcation, i.e., 0.15 ng/mL and 0.20 ng/g, for serum and breast
tissue, respectively. For the three positive controls the concentrations in the serum (20.5 and 3.4 ng/ml) and the
breast (3.74 and 1.24 ng/g) were respectively for the 20 μg EE/100 μg users and 315 pg/ml in the serum and 1.17
ng/g in the breast for the minipill user. The intracellular free fraction of LNG may be as low as 0.008 ng/g.
Conclusion(s): The concentration of LNG in breast epithelium cells in women using the LNG-IUS is very low.
Implications: The relationship between the serum and breast tissue levels of LNG was studied in women using a
LNG-IUS or oral LNG-containing contraception. Compared to oral contraception, the tissue levels of LNG in LNG-
IUS users aremuch lower in the breast. It is not knownwhat level of LNG exposure in the breast would stimulate
RANKL andWNT4 expression; such information is needed.





The levonorgestrel (LNG)-releasing intrauterine system (LNG-IUS,
Mirena®, Bayer, Germany) has been proven to be a very effective con-
traceptive. Leading organizations such as the Centers forDisease Control
(CDC), World Health Organization (WHO), and National Institute for
Health and Care Excellence (NICE) suggest that intrauterine systems
could even be used as ﬁrst-line contraception [1–3]. In many countries,
an increasing number ofwomen are currently using their fourth consec-
utive LNG-IUS andmany even continue to use it aftermenopause for en-
dometrial protection during estrogen replacement [4,5]. The LNG-IUS
induces a high LNG concentration in the endometrium [6], which offers1
landers (FWO-Vlaanderen) and
ized by the King Boudewijn
+32 9 234 35 37.
epypere).strong protection against hyperplasia. In contrast, the amount of LNG
released into the systemic circulation is very low [7], but large individ-
ual variations have been described [8]. This systemic LNG release
could be relevant for breast safety.
Some publications point out that during menopause, the use of sys-
temic synthetic progestogens (progestins) is associated with an in-
creased incidence of breast cancer [9,10]. Well-designed experimental
studies indicated that some progestogens might interfere with apopto-
sis induced by estrogen [11]. Another study indicated that progesterone
triggers the secretion ofWNT4 (Wingless-related integration site4) and
RANKL (receptor activator of nuclear factor-kappaB ligand). This signal-
ing may increase the migratory potential of breast cells [12].
Currently, the long-term breast safety of LNG-IUS users is controver-
sial. Some reports are reassuring [13,14], while others indicate an in-
crease in breast cancer risk [15–17]. Although serum LNG
concentrations have been reported in users of different types of LNG-
IUS [18], data on actual LNG concentrations in the breast are currently
lacking. Determination of these in vivo concentrations would allow
in vitro experiments to be designed to study the inﬂuence of different
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study was to measure LNG concentrations in the breast tissue of LNG-
IUS users that could be useful for planning future studies.2. Materials and methods
2.1. Patients
LNG concentrations were determined in breast tissue and in
serum of 25 healthy women undergoing reductive breast surgery
for esthetic reasons. Normal histological ﬁndings in the recovered
breast tissue were present in all women. Women with ductal hyper-
plasia were not included. A total of 18 women used the LNG-IUS.
Their ages ranged from 17 to 54 years, and the BMI range was 22 to
29 kg/m2. Four women who were not using any form of contracep-
tive served as negative controls. Two women using the 20 μg ethinyl
estradiol (EE)/100 μg LNG combined oral contraceptive (COC) and
one woman taking an oral LNG minipill (30 μg) served as positive
controls. The contraceptive tablets were taken in the morning of
the day prior to surgery by one patient (20 μg EE/100 μg LNG) and
on the day of surgery by the two other patients (20 μg EE/100 μg
LNG and 30 μg LNG). The study was approved by the UZ Gent ethical
committee (EC 2005/022–10 022011). A written consent was ob-
tained from all participating women.2.2. Breast tissue and blood sampling
Breast tissue samples (100 mg) were immediately (snap) frozen in
liquid nitrogen and stored at−80°C. The samples were kept frozen dur-
ing manual, microscopic dissection into fractions. All fat tissue was re-
moved, leaving for the most part only epithelium, blood vessels,
extensive intercellular space with connective tissue and stromal cells,
of which the proportions could not be determined. Blood samples
were obtained prior to surgery and processed to obtain serum, which
was also stored at−80°C.2.3. Assays
The determination of LNG levels was performed by an in-house val-
idated ultra-performance liquid chromatography/tandem mass spec-
trometry (UPLC-MS/MS, Xevo TQ-S, Waters, Milford, US) assay
method. A gradient elution of acidiﬁed water (0.1% formic acid) and
methanol was applied, and pumped at a constant ﬂow rate of 0.3 mL/
min onto an Acquity BEH C18 column (150 mm × 2.1 mm, 1.7 μm,
Waters).
To optimize the extraction procedure for both biological matrices,
the protocol of Moser and coworkers was followed [19]. This method
was properly validated following optimization of the extraction proto-
col. Validation of the assay comprised assessing precision (intra-lab re-
producibility), linearity (R2 of calibration line and lack-of-ﬁt of 3
calibration lines), limit of detection (LOD) and limit of quantiﬁcation
(LOQ). The deuterated internal standard levonorgestrel-d6 was used
to correct for procedural losses. Serumwas spiked for precision evalua-
tion at 0.1, 0.15 and 0.2 ng/mL LNG, and breast tissue was spiked at 0.2,
0.4 and 0.5 ng/g LNG. Relative standard deviations (RSDs) for precision
of LNG analysis were 18.4, 18.1, and 9.8% in serum and 3.5, 1.1, and 4.2%
in breast tissue, respectively. The LOD was 0.10 and 0.15 ng/g and the
LOQ was 0.15 ng/mL and 0.2 ng/g in serum and breast tissue, respec-
tively. Mean concentrations and standard deviations were calculated
for the serum and breast tissue LNG measurements. When concentra-
tions below the LOD were observed, they were set at LOD divided by
2. If concentrations between the LOD and LOQ were noted, the calcu-
lated value was assigned.3. Results
The mean LNG concentration in LNG-IUS users was 0.18±0.16
ng/mL in serum and 0.26±0.28 ng/g in breast tissue. For the negative
controls, the mean concentrations were below LOQs for both serum
and breast tissue. For the 3 positive controls, the LNG concentrations
were 20.5 and 3.37 ng/mL in serum and 3.74 and 1.24 ng/g in breast tis-
sue for the 20 μg EE/100 μg LNG users; the corresponding concentra-
tions in the minipill users were 0.31 ng/mL and 1.17 ng/g, respectively.
4. Discussion
We are the ﬁrst to measure LNG concentrations in breast tissue of
LNG-IUS users. Using a highly sensitive UPLC-MS/MS technique, our
LODs were 0.10 ng/mL and 0.15 ng/g for serum and breast tissue, re-
spectively. The serum LNG concentrations we found are in accordance
with the levels (0.218 ng/mL) reported in the literature in LNG-IUS
users [18].
A poor correlation was observed between the serum and breast tis-
sue LNG concentrations in the LNG-IUS users. This may be due to the
small sample size in our study and using data based on a single time
point.
It is clear fromour study that the breast tissue LNG concentrations in
the women taking either the LNG COC or the LNG minipill are higher
than the corresponding concentrations in the women using the LNG-
IUS. However, the oral contraceptive concentrations are based on a sin-
gle time point. To make a proper comparison of the LNG-IUS and the
LNG oral contraceptives, it is essential to estimate the steady state LNG
values over a 24-h period from the oral contraceptives. Use of a single
time point is of very limited value, and is a limitation of our study.
The available LNG data for the positive controls show that the serum
concentrations were 20.5 and 3.3 ng/mL in the COC users, whereas the
concentration in the minipill user was 0.31 ng/mL. The COC user who
had an LNG concentration of 20 ng/mL took the pill on the morning of
the day prior to surgery. The corresponding breast tissue LNG concen-
tration in this woman was 4 ng/g. Both the serum and tissue LNG levels
appear to very high and the serum value is signiﬁcantly higher than
values previously reported in literature [20,21]. As no analytical artifacts
were noted and this concentration conﬁrmed repeatedly, we hypothe-
size that this may be explained by other medication administered
and/or procedures performed to the patient prior to surgery.
In our study, we measured total LNG levels, of which approximately
97% are protein bound (sex hormone binding globulin (SHBG)-bound,
47%; albumin-bound, 50%; unbound, 3%) [22]. The unbound LNG is hy-
pothesized to be available for biologic activity in target cells as well as
prone to metabolism. However, it is possible that albumin-bound LNG,
being loosely bound, could dissociate in tissue capillaries, enter the
cell, and become bioavailable [23].
The circulating unbound LNG, like other steroids, can diffuse freely
through cell membranes and intercellular spaces [24]. The LNG concen-
tration in the breast tissue obtained during our UPLC-MS/MS quantiﬁca-
tion is indeed total LNG, but the proportions that are protein-bound and
unbound are not known. During processing of the tissue the hydrogen
bonding involved in the binding of steroids by SHBG and albumin are
destroyed. SHBG circulates as a homodimer. Each SHBG monomer con-
tains 2 domains at the N-terminal end of the protein that enable the
binding of sex steroids. The serine residue within this binding pocket
is important in androgen and estrogen binding and forms hydrogen
bonds with the ketone group at the C-3 position of certain androgens
such as testosterone and of progestins such as LNG. The hydrogen
bonds are about 10 times weaker than covalent bonds. This degree of
binding strength allows for spontaneous dissociation of the steroid.
The rate of dissociation plays a key role in determining how much of
the steroid enters target cells for binding to receptors.
Albumin is quantitatively the most abundant protein in the circula-
tion and accounts for about 60% of the total serum protein content. It
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but different afﬁnities. Albumin consists of 3 domains, which have bind-
ing pockets formed predominantly of hydrophobic and positively
charged amino acid residues. It is expected that LNG has a similar asso-
ciation constant (Ka) for albumin as testosterone (2–4×104 L/mol with
a very fast dissociation of about 1 s) [23]. The Ka of LNG for SHBG has
been reported to be 9.1×106 L/mol [25] compared to around 1×109 L/
mol for testosterone [23].
During tissue processing, we usedmicroscopic dissection of the sur-
gically removed breast tissue. All fat tissue was removed, leaving for the
most part only epithelium.
The breast tissue investigated in this study consisted of breast epi-
thelium cells, glandular lumen, blood vessels, and an extensive intercel-
lular space with connective tissue and stromal cells. Albumin and
possibly SHBG can diffuse through the vessel wall into the intercellular
space. Itmay be assumed that the some of the LNG in intercellular space
is also bound to these binding proteins [26]. Since it is generally ac-
cepted that b3% of circulating LNG is not bound to albumin or to
SHBG, the actual biologically available LNG in the breast epithelium
cells, which are the susceptible cells for breast cancer, may be substan-
tially lower. If only 3% of themeasured LNG in our breast tissue diffuses
into the cell then the ﬁnal intracellular LNG would be 0.008 ng/g.
Whether this low concentration in the breast is sufﬁcient to activate
the RANKL and/orWNT4 signaling system remains to be established.
In vitro studies have indicated possible mechanisms of action of LNG
on breast cancer cell lines, through 17β-hydroxysteroid dehydroge-
nases (17β-HSDs). LNG has a potent effect on 17β-HSD1 and 17β-
HSD2 in T47D cells. In T47D cells LNG upregulates the expression of
the reductive 17β-HSD1 and downregulates the expression of the oxi-
dative 17β-HSD2. These changes in enzyme expression lead to more
bioactive estrogen, which indicates that LNG can indirectly inﬂuence
ER activity [27,28]. At the LNG concentrations detected in breast tissue
in our study, no inﬂuence on 17β-HSD1 and 17β-HSD2 was observed
in highly sensitive T47D cells in ZR75–1 and MCF-7 cell lines.
LNGmay also enhance VEGF production. VEGF is an important factor
in the proliferation and migration of vascular endothelial cells
(i.e., angiogenesis). It is an essential step for tumor growth, expansion
andmetastasis. Again, at the LNG concentrations observed in the breast
in our study, no increases in VEGFmRNA expression has been described
in T47D cells [29]. Nevertheless, until studies have been performed at
these low LNG concentrations, LNG may still inﬂuence breast cells or
breast cancer cells that may be present subclinically.
In conclusion, low LNG concentrationswere detected in breast tissue
of women using the LNG-IUS. The observed LNG concentrations offer a
solid basis for further research regarding the inﬂuence of LNG on the
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